Palbociclib - Latest Advances

Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response.

Journal: Cancer heterogeneity and plasticity

Published: October 17, 2025

Suppression of Ovarian Cancer Cell Proliferation is Associated with Upregulation of Cell-Matrix Adhesion Programs and Integrin-β4-Induced Cell Protection from Cisplatin.

Journal: bioRxiv : the preprint server for biology

Published: October 01, 2025

Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes.

Journal: Expert review of anticancer therapy

Published: September 16, 2025

Plain language summary of a systematic review of palbociclib treatment for advanced/ metastatic breast cancer in older patients.

Journal: Future oncology (London, England)

Published: September 15, 2025

Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG).

Journal: Journal of chemotherapy (Florence, Italy)

Published: September 11, 2025

Charting the Multi-level Molecular Response to Palbociclib in ER-Positive Breast Cancer.

Journal: bioRxiv : the preprint server for biology

Published: September 05, 2025

NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.

Journal: Science translational medicine

Published: August 27, 2025

Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 27, 2025

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 22, 2025

Cyclin-dependent kinase 4/6 inhibitor ribociclib-induced colitis with a successful transition to palbociclib.

Journal: BMJ case reports

Published: August 21, 2025

Cardiovascular safety of CDK4/6 inhibitors in advance breast cancer: Assessing risks of QTc prolongation and thrombosis.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: August 20, 2025

Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study.

Journal: JCO precision oncology

Published: August 18, 2025

Filters

Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response.

Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response.

Suppression of Ovarian Cancer Cell Proliferation is Associated with Upregulation of Cell-Matrix Adhesion Programs and Integrin-β4-Induced Cell Protection from Cisplatin.

Suppression of Ovarian Cancer Cell Proliferation is Associated with Upregulation of Cell-Matrix Adhesion Programs and Integrin-β4-Induced Cell Protection from Cisplatin.

Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes.

Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes.

Plain language summary of a systematic review of palbociclib treatment for advanced/ metastatic breast cancer in older patients.

Plain language summary of a systematic review of palbociclib treatment for advanced/ metastatic breast cancer in older patients.

Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG).

Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG).

Charting the Multi-level Molecular Response to Palbociclib in ER-Positive Breast Cancer.

Charting the Multi-level Molecular Response to Palbociclib in ER-Positive Breast Cancer.

NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.

NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors.

Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.

Cyclin-dependent kinase 4/6 inhibitor ribociclib-induced colitis with a successful transition to palbociclib.

Cyclin-dependent kinase 4/6 inhibitor ribociclib-induced colitis with a successful transition to palbociclib.

Cardiovascular safety of CDK4/6 inhibitors in advance breast cancer: Assessing risks of QTc prolongation and thrombosis.

Cardiovascular safety of CDK4/6 inhibitors in advance breast cancer: Assessing risks of QTc prolongation and thrombosis.

Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study.

Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study.